Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
REGULATORY
FY2019 Tax Reform Debate Going into Full Swing; Will Pharma Industry Win Expansion in R&D Credit?
The ruling Liberal Democratic Party (LDP) is gearing up for formulating its FY2019 taxation reform outline, accelerating its communications with relevant ministries and trade associations. The pharma industry is expected to push for the maintenance and expansion of the R&D…
To read the full story
Related Article
- LDP Draws Up Tax Reform Outline, Revamps Credits for R&D Expenses
December 17, 2018
- Govt to Tap R&D Tax Credit System to Push Research on Pediatric Use, Superbug Fight
December 13, 2018
- R&D Tax Credit Refit Taking Shape; Open Innovation Scheme Likely to Cover Research Commissioned to Big Firms
December 10, 2018
- LDP Lawmakers Push for Expansion of R&D Tax Credit
November 30, 2018
- LDP Conducts Hearing with Pharma Trade Groups for FY2019 Budgets, Tax Reform
November 9, 2018
- MHLW, METI Seek 3-Year Extension for Temporary R&D Tax Credit Measures
September 3, 2018
REGULATORY
- (Update) Average NHI-Market Price Gap Narrows to 5.2% to Hit Record Low
December 4, 2024
- LDP Sees Growing Chorus of Opposition to Off-Year Revisions
December 4, 2024
- Japan Expected to Include Shingles Vaccines in NIP from FY2025
December 4, 2024
- Opposition DPP Leader Pledges to Go Full Throttle on Ending Off-Year Revisions
December 3, 2024
- Qalsody, Zepbound, Zeposia Inch Closer to Japan Approval with Panel OK
December 3, 2024
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…